Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Income (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Net Income for 14 consecutive years, with $38000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 99.09% year-over-year to $38000.0, compared with a TTM value of -$2.5 million through Dec 2025, up 77.98%, and an annual FY2025 reading of -$10.2 million, up 27.23% over the prior year.
  • Net Income was $38000.0 for Q4 2025 at Heron Therapeutics, up from -$4.1 million in the prior quarter.
  • Across five years, Net Income topped out at $4.2 million in Q4 2024 and bottomed at -$62.9 million in Q1 2022.
  • Average Net Income over 5 years is -$25.9 million, with a median of -$22.6 million recorded in 2022.
  • Peak annual rise in Net Income hit 165.74% in 2025, while the deepest fall reached 99.09% in 2025.
  • Year by year, Net Income stood at -$53.5 million in 2021, then soared by 61.98% to -$20.4 million in 2022, then skyrocketed by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then crashed by 99.09% to $38000.0 in 2025.
  • Business Quant data shows Net Income for HRTX at $38000.0 in Q4 2025, -$4.1 million in Q3 2025, and -$1.6 million in Q2 2025.